Source: Wedgewood
Wedgewood has introduced molnupiravir to its formulary, becoming the first U.S. Veterinary compounding pharmacy to offer feline-friendly formulations of the drug, which shows promise in treating Feline Infectious Peritonitis (FIP), a typically fatal disease affecting around 15,000 U.S. cats annually. Originally developed for human viral infections like COVID-19, molnupiravir has shown potential in both primary and rescue treatments for various forms of FIP (Effusive, Non-effusive, Neurological, and Ocular).
Wedgewood’s formulations include flavored oral oil suspensions and capsules in various doses tailored to individual cats. Studies from Japan and other researchers have reported significant remission in FIP-infected cats treated with molnupiravir, with minimal side effects. Nicole Jacque from FIP Global CATS noted this as a critical step forward in FIP treatment, especially for cats resistant to other antivirals. Dr. Alejandro Bernal, Wedgewood’s CEO, emphasized the importance of this treatment in improving the quality of life for affected cats.
Read the full story HERE: https://www.wedgewood.com/newsroom/wedgewood-launches-compounded-molnupiravir-for-the-treatment-of-feline-infectious-peritonitis-fip-/